within Pharmacolibrary.Drugs.S_SensoryOrgans.S01B_AntiinflammatoryAgents.S01BA09_Clobetasone;

model Clobetasone
  extends Pharmacolibrary.Drugs.ATC.S.S01BA09;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>S01BA09</td></tr><td>route:</td><td>topical</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Clobetasone is a moderately potent synthetic corticosteroid, primarily used topically to reduce inflammation and manage conditions such as eczema, psoriasis, and other inflammatory skin disorders. It is sometimes used in ophthalmic formulations (e.g. clobetasone butyrate eye drops) to reduce inflammation in allergic and inflammatory conjunctival conditions. Clobetasone is approved for use in several countries, mostly as a topical agent in dermatology and ophthalmology.</p><h4>Pharmacokinetics</h4><p>No published studies have reported detailed pharmacokinetic parameters for clobetasone (including clobetasone butyrate) in humans with ophthalmic or topical administration. Below are estimated pharmacokinetic parameters, extrapolated from general knowledge of topical corticosteroids and expected absorption based on physico-chemical properties.</p><h4>References</h4><ol><li><p>Rink, H, et al., &amp; Hockwin, O (1989). Distribution of clobetasone in rabbit eye tissues after topical application. <i>Lens and eye toxicity research</i> 6(1-2) 353–363. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/2488027/\">https://pubmed.ncbi.nlm.nih.gov/2488027</a></p></li><li><p>Hehir, M, et al., &amp; Shenoy, EV (1983). Investigation of the pharmacokinetics of clobetasol propionate and clobetasone butyrate after a single application of ointment. <i>Clinical and experimental dermatology</i> 8(2) 143–151. DOI:<a href=\"https://doi.org/10.1111/j.1365-2230.1983.tb01758.x\">10.1111/j.1365-2230.1983.tb01758.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/6851236/\">https://pubmed.ncbi.nlm.nih.gov/6851236</a></p></li><li><p>Sparidans, RW, et al., &amp; Beijnen, JH (2010). Liquid chromatography-tandem mass spectrometric assay for clobetasol propionate in human serum from patients with atopic dermatitis. <i>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences</i> 878(23) 2150–2154. DOI:<a href=\"https://doi.org/10.1016/j.jchromb.2010.06.011\">10.1016/j.jchromb.2010.06.011</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/20605116/\">https://pubmed.ncbi.nlm.nih.gov/20605116</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Clobetasone;
